University of Oxford Announces Opening of PanDox Phase 1 Study investigating Targeted Drug Delivery by Focused Ultrasound for Pancreatic Cancer
1 July 2021
The University of Oxford is pleased to announce commencement of enrollment for the Phase I PanDox study of thermosensitive liposomal doxorubicin triggered by focused ultrasound in patients with pancreatic cancer.
24 June 2021
Dr Lee (Department of Oncology) received the award to acknowledge his contributions during the COVID-19 pandemic, through the establishment of the UK Coronavirus Cancer Monitoring Project.
8 April 2021
Initial success leads to new award for Oxford researcher pushing forward new cancer-hunting radiotherapy despite lockdown.
25 March 2021
A new ViewRay MRIdian machine is the first of its kind in the UK and will be used by the University of Oxford, OUH and GenesisCare to help improve challenging cancer treatment through faster, tailored radiotherapy.
17 February 2021
Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.
2 December 2020
Early findings from a study into longer-term damage amongst patients recovering from COVID-19 suggest that the use of cutting-edge scanning techniques may detect previously unseen lung damage.
20 October 2020
Prof. Sibson together with her co-applicants Prof. Anthony, Dr Campbell and Prof. Middleton have now been awarded a second MRC DPFS grant, for £3.3 million, to acquire further preclinical data to support the case for clinical translation, to develop the mutTNF production for human use and to undertake pre-clinical toxicology.
20 August 2020
Prof. Anne Kiltie and her team discuss their important work into the effects of radiosensitisation on ageing cancer patients with the CRUK Science Blog.
27 July 2020
Congratulations to Professor Anna Schuh and her team who are the Winners of the Teamwork category in the Vice-Chancellor Innovation Awards 2020 for their work on SEREN_A Social Enterprise to deliver DNA-based diagnostics that improves outcomes of children and young adults with blood diseases in sub-Saharan Africa.
22 July 2020
Understanding the molecular subtype of a cancer is becoming an importance part of the diagnostic process as it helps a doctor better understand a patient’s prognosis, determine the best course of action for treatment and helps researchers devise new, more-efficient, precision therapies.
8 July 2020
Professor Nicola Sibson has been involved in the CNIO platform to compile a repository for brain metastasis cell lines.
3 July 2020
UK Research and Innovation, Cancer Research UK and industry are investing more than £11 million in an Oxford-led artificial intelligence (AI) research programme to improve the diagnosis of lung cancer and other thoracic diseases.
23 April 2020
Many congratulations to Dr Mark Hill, who has become a Fellow of the Society for Radiological Protection (FSRP).
26 March 2020
UK National Cancer Imaging Translational Accelerator (NCITA) establishes infrastructure for validation and adoption of cancer imaging biomarkers as decision-making tools in clinical trials and NHS practice. Researchers and medical experts from nine world-leading medical imaging centres across the UK come together to form an integrated infrastructure for standardising and validating cancer imaging biomarkers for clinical use.